[go: up one dir, main page]

EA201391114A1 - Способы использования alk-ингибиторов - Google Patents

Способы использования alk-ингибиторов

Info

Publication number
EA201391114A1
EA201391114A1 EA201391114A EA201391114A EA201391114A1 EA 201391114 A1 EA201391114 A1 EA 201391114A1 EA 201391114 A EA201391114 A EA 201391114A EA 201391114 A EA201391114 A EA 201391114A EA 201391114 A1 EA201391114 A1 EA 201391114A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
methods
alk
use alk
eml4
Prior art date
Application number
EA201391114A
Other languages
English (en)
Other versions
EA023404B1 (ru
Inventor
Наньсинь Ли
Дженнифер Л. Харрис
Питер МакНамара
Фансянь Сунь
Original Assignee
АйАрЭм ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by АйАрЭм ЭлЭлСи filed Critical АйАрЭм ЭлЭлСи
Publication of EA201391114A1 publication Critical patent/EA201391114A1/ru
Publication of EA023404B1 publication Critical patent/EA023404B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предложены способы использования соединений формулы I для лечения опосредованных EML4-ALKсостояний, например EML4-ALKнемелкоклеточного рака легких (NSCLC), необязательно устойчивого к кризотинибу; где R, R, R, R, Rи Rописаны выше.
EA201391114A 2011-02-02 2012-02-02 Способ лечения немелкоклеточного рака легких EA023404B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (2)

Publication Number Publication Date
EA201391114A1 true EA201391114A1 (ru) 2013-12-30
EA023404B1 EA023404B1 (ru) 2016-05-31

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391114A EA023404B1 (ru) 2011-02-02 2012-02-02 Способ лечения немелкоклеточного рака легких

Country Status (22)

Country Link
US (1) US8703787B2 (ru)
EP (1) EP2670401B1 (ru)
JP (1) JP5837095B2 (ru)
KR (1) KR101521861B1 (ru)
CN (1) CN103458881B (ru)
AU (1) AU2012212142B2 (ru)
BR (1) BR112013019643B1 (ru)
CA (1) CA2824092C (ru)
CY (1) CY1116662T1 (ru)
DK (1) DK2670401T3 (ru)
EA (1) EA023404B1 (ru)
ES (1) ES2543567T3 (ru)
HR (1) HRP20150946T1 (ru)
HU (1) HUE025395T2 (ru)
ME (1) ME02200B (ru)
MX (1) MX2013008791A (ru)
PL (1) PL2670401T3 (ru)
PT (1) PT2670401E (ru)
RS (1) RS54189B1 (ru)
SI (1) SI2670401T1 (ru)
SM (1) SMT201500300B (ru)
WO (1) WO2012106540A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2675850C2 (ru) 2012-11-06 2018-12-25 Шанхай Фокон Фармасьютикал Ко Лтд Ингибиторы alk-киназы
KR20150081344A (ko) * 2012-11-07 2015-07-13 노파르티스 아게 조합 요법
CN104109149B (zh) 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
JP6510510B2 (ja) 2013-07-11 2019-05-08 ベータ ファーマシューティカルズ カンパニー リミテッド プロテインチロシンキナーゼモジュレーター及び使用方法
ES2674361T3 (es) * 2013-08-28 2018-06-29 Novartis Ag Combinación de un inhibidor de ALK y un inhibidor de CDK para el tratamiento de enfermedades celulares proliferativas
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2015194764A2 (ko) * 2014-06-17 2015-12-23 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
CN106220644B (zh) 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
US10709705B2 (en) * 2016-08-29 2020-07-14 The Regents Of The University Of Michigan Aminopyrimidines as ALK inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
US20090236334A1 (en) 2006-07-10 2009-09-24 Rf Dynamics Ltd Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP5208123B2 (ja) 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CN102131788B (zh) * 2008-04-07 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物

Also Published As

Publication number Publication date
CA2824092C (en) 2020-06-30
BR112013019643A2 (pt) 2016-10-04
HRP20150946T1 (hr) 2015-10-09
HUE025395T2 (en) 2016-02-29
MX2013008791A (es) 2013-10-07
CA2824092A1 (en) 2012-08-09
CY1116662T1 (el) 2017-03-15
WO2012106540A1 (en) 2012-08-09
CN103458881A (zh) 2013-12-18
DK2670401T3 (en) 2015-09-07
RS54189B1 (en) 2015-12-31
SMT201500300B (it) 2016-01-08
KR101521861B1 (ko) 2015-05-21
US8703787B2 (en) 2014-04-22
EA023404B1 (ru) 2016-05-31
CN103458881B (zh) 2015-08-12
JP2014504646A (ja) 2014-02-24
AU2012212142B2 (en) 2015-09-24
BR112013019643B1 (pt) 2022-04-19
SI2670401T1 (sl) 2015-10-30
ME02200B (me) 2016-02-20
AU2012212142A1 (en) 2013-08-15
EP2670401A1 (en) 2013-12-11
PT2670401E (pt) 2015-10-12
ES2543567T3 (es) 2015-08-20
JP5837095B2 (ja) 2015-12-24
KR20130121174A (ko) 2013-11-05
EP2670401B1 (en) 2015-06-10
PL2670401T3 (pl) 2015-11-30
US20130296357A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
EA201391114A1 (ru) Способы использования alk-ингибиторов
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
PH12017502141A1 (en) Compounds and their methods of use
TR201816379T4 (tr) DNA-PK inhibitörleri.
PH12012502128B1 (en) Chemical compounds
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA024630B9 (ru) Производные пиразола как ингибиторы ионных каналов, активируемых высвобождением кальция (crac)
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
IN2015DN01156A (ru)
TN2014000063A1 (en) Kinase inhibitor polymorphs
MX2015000129A (es) Derivados de pirimidin pirazolilo.
GB201103062D0 (en) Method
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
MX358303B (es) Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
MX2013010898A (es) Novedoso derivados de la pirimidina.
IN2015DN01151A (ru)
PH12015501088A1 (en) Dimeric compounds
EA201391396A1 (ru) Макроциклические соединения и способы их получения
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
PH12015500399A1 (en) Azaindolines

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM